3 terminated, 1 recruiting. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 3, Recruiting 1 |
| Phase 2 | 2 | Terminated 2 |
Follow Relapsed or Refractory Acute Myeloid Leukemia (AML): new trials by email Literature Review of Relapsed or Refractory Acute Myeloid Leukemia (AML) trials Research Report on Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia Mitoxantrone Hydrochloride Liposome - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Terminated | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 | 2022-06-14 | 2024-02-23 |
| An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) KRT-232, Cytarabine, Decitabine - Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN) | Phase 1 / Phase 2 | Terminated | Kartos Therapeutics, Inc. | 70 | 2019-09-25 | 2024-03-22 |
| Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. AZD5991, AZD5991 + Venetoclax - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Terminated | AstraZeneca | 70 | 2017-08-02 | 2022-09-23 |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation AG-120 - Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML | Phase 1 | Recruiting | Institut de Recherches Internationales Servier | 291 | 2014-03-01 | 2026-06-15 |
Leukemia, Myeloid, Acute (4) · Recurrence (4) · Hematologic Neoplasms (1) · Myelodysplastic Syndromes (1)
Disease Attributes (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Leukemia (4) · Leukemia, Myeloid (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bone Marrow Diseases (1) · Neoplasms by Site (1)
AZD5991 (1) · Cytarabine (1) · Decitabine (1) · ivosidenib (1) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1) · venetoclax (1)
AstraZeneca (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Institut de Recherches Internationales Servier (1) · Kartos Therapeutics, Inc. (1)
United States (3) · France (2) · Australia (1) · Belgium (1) · China (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1)
PMID 27245312, PMID 29860938, PMID 30559424, PMID 31841594, PMID 32296873, PMID 32380538, PMID 33493392, PMID 37380821, PMID 38640348